logo
#

Latest news with #SilexionTherapeuticsCorp

Silexion Therapeutics Corp (SLXN)'s RNAi Therapy Blocks 90% of Colorectal Tumors
Silexion Therapeutics Corp (SLXN)'s RNAi Therapy Blocks 90% of Colorectal Tumors

Yahoo

time30-05-2025

  • Business
  • Yahoo

Silexion Therapeutics Corp (SLXN)'s RNAi Therapy Blocks 90% of Colorectal Tumors

Silexion Therapeutics Corp (NASDAQ:SLXN) has announced breakthrough preclinical results for its next-generation RNA interference (RNAi) therapy, SIL204, showing potent anti-tumor effects across three major KRAS-driven cancers: pancreatic, colorectal, and lung (NSCLC). In laboratory studies, SIL204 achieved an impressive ~90% inhibition rate in GP2D human colorectal cancer cells, with significant, dose-dependent reductions also observed in pancreatic (Panc-1) and lung (A427) cancer cell lines harboring the KRAS G12D mutation. This marks a major advance, as KRAS mutations are among the most common and challenging targets in oncology, driving roughly 90% of pancreatic, 45% of colorectal, and 35% of non-squamous NSCLC cases. A hand holding cancer cells with a magnifying glass, highlighting the company's target of curing diseases. SIL204's innovative lipid-conjugated delivery system enhances cellular uptake, enabling high efficacy at nanomolar concentrations and potentially overcoming resistance that limits conventional therapies. The company plans further preclinical studies focusing on lung cancer cell lines to expand the evidence base. With a global market opportunity exceeding $30 billion for these cancer types, Silexion Therapeutics Corp (NASDAQ:SLXN)'s RNAi approach could reshape treatment options for patients with hard-to-treat, KRAS-driven tumors. While we acknowledge the potential of SLXN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SLXN and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None.

Silexion Therapeutics Corp (SLXN)'s RNAi Therapy Blocks 90% of Colorectal Tumors
Silexion Therapeutics Corp (SLXN)'s RNAi Therapy Blocks 90% of Colorectal Tumors

Yahoo

time30-05-2025

  • Business
  • Yahoo

Silexion Therapeutics Corp (SLXN)'s RNAi Therapy Blocks 90% of Colorectal Tumors

Silexion Therapeutics Corp (NASDAQ:SLXN) has announced breakthrough preclinical results for its next-generation RNA interference (RNAi) therapy, SIL204, showing potent anti-tumor effects across three major KRAS-driven cancers: pancreatic, colorectal, and lung (NSCLC). In laboratory studies, SIL204 achieved an impressive ~90% inhibition rate in GP2D human colorectal cancer cells, with significant, dose-dependent reductions also observed in pancreatic (Panc-1) and lung (A427) cancer cell lines harboring the KRAS G12D mutation. This marks a major advance, as KRAS mutations are among the most common and challenging targets in oncology, driving roughly 90% of pancreatic, 45% of colorectal, and 35% of non-squamous NSCLC cases. A hand holding cancer cells with a magnifying glass, highlighting the company's target of curing diseases. SIL204's innovative lipid-conjugated delivery system enhances cellular uptake, enabling high efficacy at nanomolar concentrations and potentially overcoming resistance that limits conventional therapies. The company plans further preclinical studies focusing on lung cancer cell lines to expand the evidence base. With a global market opportunity exceeding $30 billion for these cancer types, Silexion Therapeutics Corp (NASDAQ:SLXN)'s RNAi approach could reshape treatment options for patients with hard-to-treat, KRAS-driven tumors. While we acknowledge the potential of SLXN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SLXN and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None. Sign in to access your portfolio

Silexion Therapeutics Completes Key Preclinical Studies Exploring SIL204's Potential Impact on Colorectal and Lung Cancer
Silexion Therapeutics Completes Key Preclinical Studies Exploring SIL204's Potential Impact on Colorectal and Lung Cancer

Yahoo

time21-05-2025

  • Business
  • Yahoo

Silexion Therapeutics Completes Key Preclinical Studies Exploring SIL204's Potential Impact on Colorectal and Lung Cancer

Silexion's new groundbreaking study explores the potential impact of its next generation RNAI therapeutic candidate beyond pancreatic cancer aiming to address critical unmet needs in additional KRAS-driven tumor types with treatment markets estimated at over $30 Billion Dollars a year GRAND CAYMAN, Cayman Islands, May 21, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp (NASDAQ: SLXN) ('Silexion' or the 'Company'), a clinical-stage biotech company developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the completion of a comprehensive preclinical study assessing SIL204's therapeutic potential across multiple cancer types beyond pancreatic cancer. The Company is currently finalizing its analysis of the data and expects to announce comprehensive results within the next few days. The now-completed studies evaluated SIL204, the Company's next-generation RNAi therapeutic candidate, in multiple cancer cell lines harboring KRAS mutations: GP2D (colorectal cancer), A427 (lung cancer), and Panc-1 (pancreatic cancer). These cancer types were strategically selected based on their high prevalence of KRAS mutations and significant unmet medical needs. "Completing this expanded preclinical evaluation represents an important milestone in our SIL204 development program," said Ilan Hadar, Chairman and CEO of Silexion Therapeutics. "While our initial focus has been on pancreatic cancer, we recognized the potential of our RNAi approach to address other KRAS-driven malignancies. We look forward to sharing the detailed results from these studies in the coming days after completing the final analysis of the studies data. If positive, we believe these results have the potential to significantly expand our development strategy going forward." KRAS mutations are among the most common oncogenic drivers in human cancers, occurring in roughly 90% of pancreatic cancers, about 45% of colorectal cancers, and around 35% of non-squamous non-small-cell lung cancers. Together, these three indications underpin global treatment markets already worth well over US $30 billion a year1, yet most KRAS variants remain difficult to drug with small-molecule or antibody approaches—underscoring the potential significance of Silexion's RNAi-based strategy. About Silexion TherapeuticsSilexion Therapeutics is a pioneering clinical-stage, oncology-focused biotechnology company developing innovative RNA interference (RNAi) therapies to treat solid tumors driven by KRAS mutations, the most common oncogenic driver in human cancers. The Company's first-generation product, LODER™, has shown promising results in a Phase 2 trial for non-resectable pancreatic cancer. Silexion is also advancing its next-generation siRNA candidate, SIL204, designed to target a broader range of KRAS mutations and showing significant potential in preclinical studies. The Company remains committed to pushing the boundaries of therapeutic innovation in oncology, with a focus on improving outcomes for patients with difficult-to-treat cancers. For more information please visit: Notice Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical fact contained in this communication, including statements regarding Silexion's business strategy, ongoing preclinical studies evaluating SIL204 in colorectal and lung cancer applications, potential expansion of development strategy, plans to announce comprehensive results in the coming days, and the therapeutic potential of SIL204 across multiple cancer types, are forward-looking statements. These forward-looking statements are generally identified by terminology such as "may", "should", "could", "might", "plan", "possible", "project", "strive", "budget", "forecast", "expect", "intend", "will", "estimate", "anticipate", "believe", "predict", "potential" or "continue", or the negatives of these terms or variations of them, or similar terminology. Forward-looking statements involve a number of risks, uncertainties, and assumptions, and actual results or events may differ materially from those projected or implied by those statements. Important factors that could cause such differences include, but are not limited to: (i) Silexion's ability to successfully complete preclinical studies and initiate clinical trials; (ii) Silexion's strategy, future operations, financial position, projected costs, prospects, and plans; (iii) the impact of the regulatory environment and compliance complexities; (iv) expectations regarding future partnerships or other relationships with third parties; (v) Silexion's future capital requirements and sources and uses of cash, including its ability to obtain additional capital; (vi) Silexion's ability to maintain its Nasdaq listing; and (vii) other risks and uncertainties set forth in the documents filed or to be filed with the SEC by the Company, including the Company's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 18, 2025. Silexion cautions you against placing undue reliance on forward-looking statements, which reflect current beliefs and are based on information currently available as of the date a forward-looking statement is made. Forward-looking statements set forth herein speak only as of the date they are made. Silexion undertakes no obligation to revise forward-looking statements to reflect future events, changes in circumstances, or changes in beliefs, except as otherwise required by law. Company ContactSilexion Therapeutics CorpMs. Mirit Horenshtein Hadar, CFOmirit@ Markets & IR ContactArx Capital MarketsNorth American Equities Desksilexion@ 1 (i) Pancratic Cancer Treatment Mark; (ii) Colorectal Cancer Therapeutics Market; (iii) NSCLC Lunc Cancer Therapeutics MarketError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models
Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models

Yahoo

time28-01-2025

  • Business
  • Yahoo

Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models

New preclinical findings provide validation for Silexion's new systemic administration approach for SIL-204, demonstrating inhibition of tumor growth in a clinically relevant orthotopic model; Further studies aim to evaluate its impact on metastases Cayman Islands, January 28, 2025 – Silexion Therapeutics Corp. (NASDAQ: SLXN) ('Silexion' or the 'Company'), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced promising new preclinical data for SIL-204, its next-generation siRNA therapeutic candidate. The findings contribute to validating systemic administration as an effective delivery approach, demonstrating significant tumor growth reduction in orthotopic pancreatic cancer models, a platform designed to mimic human cancer progression. This data underscores SIL-204's potential to address one of the most aggressive and challenging cancers, validating its ability to target KRAS mutations systemically while achieving prolonged therapeutic activity. While the current data shows robust tumor growth inhibition, further studies aim to evaluate its impact on metastases, which the Company is cautiously optimisic about. The Company is actively exploring how this promising data can inform an expanded next-generation treatment strategy for KRAS-driven cancers and expects to announce details of its expanded development plan shortly. Key Preclinical Data Highlights SIL-204 administered in an extended release formulation reduced tumor growth by ~50% after 30 days, with ~50% of tumors showing complete necrosis, in human pancreatic tumors harboring a G12D mutation xenografted into mice. SIL-204 administered subcutaneously inhibited tumor growth in mouse metastatic pancreatic orthotopic models. A single systemic administration of SIL-204 maintained effective drug levels in rat plasma and tissues for over 56 days. SIL-204 inhibits key oncogenic KRAS mutations, including G12D, G12V, G12R, Q61H, and G13D. Intratumoral administration of SIL-204 microparticles reduced tumor cell numbers by ~3-fold, tumor area by ~1.5-fold, and increased tumor necrosis by ~5-fold after 15 days in human pancreatic cancer xenograft harboring a KRAS G12V mutation in mice. 'We are thrilled to share these results, which showcase systemic administration as an effective method for targeting KRAS-driven cancers,' Mitchell Shirvan, Ph.D., CSO of Silexion. 'By demonstrating robust tumor growth inhibition in a clinically relevant model, SIL-204 shows significant potential to address advanced cancers. We look forward to future studies evaluating its impact on metastatic progression.' About Silexion TherapeuticsSilexion Therapeutics is a pioneering clinical-stage, oncology-focused biotechnology company developing innovative RNA interference (RNAi) therapies to treat solid tumors driven by KRAS mutations, the most common oncogenic driver in human cancers. The company's first-generation product, LODER™, has shown promising results in a Phase 2 trial for non-resectable pancreatic cancer. Silexion is also advancing its next-generation siRNA candidate, SIL-204, designed to target a broader range of KRAS mutations and showing significant potential in preclinical studies. The company remains committed to pushing the boundaries of therapeutic innovation in oncology, with a focus on improving outcomes for patients with difficult-to-treat cancers. For more information please visit: Notice Regarding Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical fact contained in this communication, including statements regarding Silexion's business strategy and ongoing studies are forward-looking statements. These forward-looking statements are generally identified by terminology such as "may", "should", "could", "might", "plan", "possible", "project", "strive", "budget", "forecast", "expect", "intend", "will", "estimate", "anticipate", "believe", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements involve a number of risks, uncertainties, and assumptions, and actual results or events may differ materially from those projected or implied in those statements. Important factors that could cause such differences include, but are not limited to: (i) Silexion's ability to successfully complete preclinical studies and initiate clinical trials; (ii) Silexion's strategy, future operations, financial position, projected costs, prospects, and plans; (iii) the impact of the regulatory environment and compliance complexities; (iv) expectations regarding future partnerships or other relationships with third parties; (v) Silexion's future capital requirements and sources and uses of cash, including its ability to obtain additional capital; and (vi) other risks and uncertainties set forth in the documents filed or to be filed with the SEC by the company, including the proxy statement/prospectus filed with the SEC on July 17, 2024. Silexion cautions you against placing undue reliance on forward-looking statements, which reflect current beliefs and are based on information currently available as of the date a forward-looking statement is made. Forward-looking statements set forth herein speak only as of the date they are made. Silexion undertakes no obligation to revise forward-looking statements to reflect future events, changes in circumstances, or changes in beliefs, except as otherwise required by ContactSilexion Therapeutics CorpMs. Mirit Horenshtein Hadar, CFOmirit@ Markets & IR ContactArx | Capital Markets AdvisorsNorth American Equities Desksilexion@ in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store